author-photo

Guy Vigers

Laboratory of Molecular Biology

40

Papers

2462

Citations

Citation Trend

Filter By

Papers (30) Sort By

Journal Conference Others

Abstract B30: Structure-based drug discovery of MRTX1257, a selective, covalent KRAS G12C inhibitor with oral activity in animal models of cancer

2020 Molecular Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer.

2020 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (71)
Abstract LB-271: Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257, a novel KRAS G12C mutant selective small molecule inhibitor

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2.

2019 Proceedings of the National Academy of Sciences of the United States of America
Show All
- Source
- Cite
- Save
Citations (12)
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients

2019 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (350)
Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (4)
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

2018 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (28)
Inhibiteurs de kras g12c

2017
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 666: Activity of the MEK inhibitor Binimetinib (MEK162) in combination with paclitaxel in patient-derived xenograft models of high-grade serous ovarian carcinoma

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B192: Identification and characterization of highly potent and selective RET kinase inhibitors for the treatment of RET-driven cancers

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (3)